Earnings ·
Reports Q3 revenue of $24.9M, raises full-year guidance to $92M-$93M
SGHTSight Sciences, Inc.
Sight Sciences reported third-quarter revenue of $24.9 million, a 25% increase from the prior year, driven by record Interventional Dry Eye sales of $3.9 million and Interventional Glaucoma revenue of $21.0 million. The company raised its full-year 2026 revenue guidance to $92 million–$93 million, up from the previous range of $88 million–$92 million, while maintaining adjusted operating expense guidance of $92 million–$94 million. Net loss improved to $6.8 million from $8.2 million in the prior-year quarter, and cash usage decreased 74% year-over-year. Sight Sciences is an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives.